Clinicaltrials.gov identifier:
NCT04194554 (https://clinicaltrials.gov/show/NCT04194554)
Treatment
Newly diagnosed prostate cancer grade group 3-5
Study Contact Information:
For additional information, contact:
Cancer AnswerLine: 800-865-1125
or by email at: [email protected]
This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.
This is an open label, single-group study.
All study participants will receive the following:
Michigan
Ann Arbor, MI
University of Michigan Rogel Cancer Center
Contact: Cancer AnswerLine: 800-865-1125
or by email at: [email protected]
Principal Investigator: William Jackson, MD
New York
New York, NY
Weill Cornell Medicine
Contact: Sharanya Chandrasekhar, MS: 646-962-2196
or by email at: [email protected]
Contact: Pragya Yadav, PhD: 646-962-2199
or by email at: [email protected]
Principal Investigator: Himanshu Nagar, MD
Ohio
Cleveland, OH
University Hospitals Seidman Cancer Center
Contact: Daniel Spratt, MD: 216-293-6191
or by email at: [email protected]
Principal Investigator: Daniel Spratt, MD
Texas
Dallas, TX
University of Texas Southwestern
Contact: Cancer AnswerLine at UTSW: 833-722-6237
or by email at: [email protected]
Principal Investigator: Neil Desai, MD, MHS
Men age 18 years or older who meet the following criteria:
People with the following are not eligible:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.